Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin

US FDA Clears Monotherapy Use

 
• By Joseph Haas
  
Research scientist
Seagen's ADC Tivdak, partnered with Genmab, obtains US approval, positions for other indications
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D